Global Markets Direct’s, ‘Otitis Media - Pipeline Review, H1 2019’, provides an overview of the Otitis Media pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Otitis Media, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Otitis Media
- The report reviews pipeline therapeutics for Otitis Media by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Otitis Media therapeutics and enlists all their major and minor projects
- The report assesses Otitis Media therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Otitis Media
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Otitis Media
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Lee's Pharmaceutical Holdings Ltd
Madam Therapeutics BV
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
Novus Therapeutics Inc
Yuhan Corp
Lee's Pharmaceutical Holdings Ltd
Madam Therapeutics BV
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
Novus Therapeutics Inc
Yuhan Corp
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Otitis Media - Overview
Otitis Media - Therapeutics Development
Pipeline ...
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Otitis Media - Overview
Otitis Media - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Otitis Media - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Otitis Media - Companies Involved in Therapeutics Development
Lee's Pharmaceutical Holdings Ltd
Madam Therapeutics BV
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
Novus Therapeutics Inc
Yuhan Corp
Otitis Media - Drug Profiles
(cholesteryl palmitate + colfosceril palmitate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(dexamethasone + piperacillin + tazobactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
finafloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazufloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PCL-1440 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pneumococcal (13-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pneumococcal (23-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Otitis Media - Dormant Projects
Otitis Media - Product Development Milestones
Featured News & Press Releases
Jan 30, 2019: Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials
Jan 10, 2019: Novus doses first patient in Phase I trial of OP0201
Dec 04, 2018: Novus Therapeutics announces formation of Scientific Advisory Board
Nov 28, 2018: Novus Therapeutics doses first subject in Phase I trial of OP0201
Jun 19, 2018: Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media
Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media
Oct 29, 2012: Study Suggests New Way to Prevent Recurrent Ear Infections
Apr 18, 2012: MerLion Initiates Phase III Clinical Program To Evaluate Finafloxacin For Treatment Of Acute Otitis Media
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
List of Tables
Number of Products under Development for Otitis Media, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products ...
List of Tables
Number of Products under Development for Otitis Media, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Otitis Media - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2019
Otitis Media - Pipeline by Madam Therapeutics BV, H1 2019
Otitis Media - Pipeline by Merck & Co Inc, H1 2019
Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2019
Otitis Media - Pipeline by Novus Therapeutics Inc, H1 2019
Otitis Media - Pipeline by Yuhan Corp, H1 2019
Otitis Media - Dormant Projects, H1 2019
List of Figures
List of Figures
Number of Products under Development for Otitis Media, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products ...
List of Figures
Number of Products under Development for Otitis Media, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019